DAY	TIME	AUDITORIUM	SALA ONICE
			Nurse Session 1
MONDAY 19	9:30 - 11:00 A. M.		Haematology issues (A. Babic)
	11:00 - 11:30 A. M.	COFFEE BREAK	
	11:30 - 1:00 P. M.		Basic Apheresis (M. Neyrinck) Calculation in Apheresis (M. Neyrinc
	2:00 P. M.	OPENING REMARKS (A. Bosi M. Lozano)	
	2:30 - 3:15 P. M.	Lecture: CLINICAL APHERESIS: STATE OF ART (G. Rock)	
		Session 1 STATE OF ART IN CELLULAR THERAPY (F. Lanza, G. Rock)	
	3:15 - 4:30 P. M.	- Peripheral blood stem cell procurement as standard treatment for hematologic malignancies ( <i>R. Moog</i> ) - Lymphocyte collection for DLI and Adoptive Immunotherapy ( <i>A. Bosi</i> ) - PBSC Collection technologies and graft composition ( <i>B. Calmels</i> )	
	4:30 - 4:45 P. M.	COFFEE BREAK	
		Session 2 STATE OF ART IN CELLULAR THERAPY (G. De Silvestro, P. Perseghin)	
	4:45 - 6:30 P. M.	- Immune effector clinical depletion in haploidentical transplant (S. Rutella)  - Improving the autologous graft by optimizing cryoprotectant and cell washing (R. Saccardi)  - Collection, Expansion and Clinical use of MSC (P. ludicone)  - Clinical estimation of PBSC content in frozen/thawed products (F. Lanza)  - Discussion	
	8:00 P. M.	OPENING EVENT	
TUESDAY 20		Session 3 REGULATORY ISSUES (M. Lozano, A. Mazzoni)	
	8:30 - 10:00 A. M.	- Regulatory standards involving clinical apheresis worldwide (C. Jr. Andrzejewski)  - Outcome of JACIE standard application in collection and processing units (E. McGrath)  - A working Hypotesis: a sectorial standard for therapeutic apheresis (M. Lozano)  - Discussion	
	10.00 - 10:30 A. M.	COFFEE BREAK	
		Session 4 DONOR ISSUES (P. Accorsi, R. Moog)	
	10:30 - 12:00 A. M.	- Donor's care and laboratory examinations in donor apheresis (L. Infanti)  - Donor Apheresis technologies in the third millennium (J. L. Winters)  - Blood Donation and Donor Apheresis in Europe: the search for the "Golden Proportion" (H. Vrielink)  - Discussion	
	12:30 - 1:30 P. M.	LUNCH WORHSHOP	
		Session 5 THERAPEUTIC APHERESIS (J. L. Winters, A. Zanella)	
	2:00 - 3:30 P. M.	- Continuous promotion of clinical evidences and appropriateness in therapeutic apheresis (Z. M. Szczepiorkowski) - Emergent indications in therapeutic apheresis (P. Perseghin) - To imagine a role for ECP in GVHD prophylaxis (A. Bacigalupo) - Discussion	
	3:30 - 4:00 P. M.	COFFEE BREAK	
		Session 6 ORAL COMMUNICATIONS (A. Ostuni, G. Russi)	Nurse Session 3
	4:00 - 5:30 P. M.	Presentation of 8 oral communications	- Quality in apheresis ( <i>H. Vrielink</i> - Adverse events in apheresis ( <i>M. Neyrinck</i> ) - Open questions and discussions ( <i>A. Babic</i> )